Morgan Stanley Raises Price Target on Recursion Pharmaceuticals (RXRX)
On May 14, 2026, Morgan Stanley raised its price target for Recursion Pharmaceuticals (NASDAQ:RXRX) to $5.50 from $5 while maintaining an Equal Weight rating. The company reported Q1 earnings and revenue below estimates but maintains a strong cash position with funds expected to last until early 2028.
